Patrick Horn, MD, PhD, explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.
Patrick Horn, MD, PhD, chief medical officer at Tetraphase Pharmaceuticals explains why eravacycline is a unique antibiotic and how it stands up against many different types of pathogens, including those that are multidrug-resistant.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.